This is NOT the copy of the FDA letter that was circulated just recently. This relates to the concerns in advance of that letter. However, should the FDA ultimately require intellicell to seek approval, it will open a very wide door to the entire group and a slippery slope to other existing therapies that they do not require approval for.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.